Proposed are a pharmaceutical composition for cancer treatment, comprising a prion protein-specific antibody, and a pharmaceutical composition for cancer treatment, comprising a complex of a target that binds to a prion protein antigenic determinant, and one or more selected from the group consisting of an anticancer drug, a chemotherapeutic agent, a toxin, a radioisotope, and a cytotoxic enzyme.

The present disclosure is directed to a multi-species prion protein or peptide thereof, and vaccine compositions comprising the same that are useful for the vaccination and treatment of mammalian subjects at risk of having or having prion disease. Also disclosed herein are isolated proteins and peptides, polymers, vaccines, animal bait or feed, antibodies, and methods of inhibiting the onset of or treating a prion disease.

Provided are methods and agents for depleting senescent cells endogenous to a subject, involving administering to the subject a binding agent that is selectively toxic to senescent cells in an amount effective to reduce the number of such cells, wherein the binding agent binds selectively to a senescent cell surface protein having a misfolded conformation, relative to said protein in a native conformation.

Described herein are doppel-targeting molecules useful for inhibiting pathological angiogenesis and treating diseases and conditions associated with pathological angiogenesis, such as tumors, cancers, atherosclerosis, tuberculosis, asthma, pulmonary arterial hypertension (PAH), neoplasms and neoplasm-related conditions, and for detecting doppel expression in a subject. Related compositions and methods also are described.

The present disclosure relates generally to polypeptides, which may be used of the treatment of neurological diseases or disorders.

The invention relates to diagnosis, prevention, and treatment of diseases and conditions associated with the functions of prion-like or Tetz-proteins.

The present disclosure provides antibodies and antigen-binding fragments capable of binding PrP.sup.C. The disclosure further provides methods for making and using the antibodies and antigen-binding fragments.

The present disclosure provides antibodies and antigen-binding fragments capable of binding PrP.sup.C. The disclosure further provides methods for making and using the antibodies and antigen-binding fragments.

The present invention provides ligands capable of binding to prion protein, such as anti-prion protein antibodies and antigen-binding fragment thereof, for the prevention and/or treatment of synucleinopathies, such as Parkinson's disease. The present invention also provides pharmaceutical compositions comprising such ligands and methods for treating synucleinopathies or for reducing the uptake of -synuclein fibrils.

The present invention is directed to an anti-prion monoclonal antibody and its use for the treatment of conditions associated with or mediated by proteins or peptides having a toxic oligomeric form. These conditions include, but are not limited to, Alzheimer's disease, frontotemporal dementias, traumatic brain injury, and chronic traumatic encephalopathy.